rs137852340
Positions:
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PP5_Very_Strong
The NM_001360016.2(G6PD):āc.95A>Gā(p.His32Arg) variant causes a missense change. The variant allele was found at a frequency of 0.0000306 in 1,209,146 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 10 hemizygotes in GnomAD. Variant has been reported in ClinVar as Likely pathogenic (ā ā ).
Frequency
Genomes: š 0.000072 ( 0 hom., 5 hem., cov: 23)
Exomes š: 0.000026 ( 0 hom. 5 hem. )
Consequence
G6PD
NM_001360016.2 missense
NM_001360016.2 missense
Scores
7
7
3
Clinical Significance
Conservation
PhyloP100: 5.99
Genes affected
G6PD (HGNC:4057): (glucose-6-phosphate dehydrogenase) This gene encodes glucose-6-phosphate dehydrogenase. This protein is a cytosolic enzyme encoded by a housekeeping X-linked gene whose main function is to produce NADPH, a key electron donor in the defense against oxidizing agents and in reductive biosynthetic reactions. G6PD is remarkable for its genetic diversity. Many variants of G6PD, mostly produced from missense mutations, have been described with wide ranging levels of enzyme activity and associated clinical symptoms. G6PD deficiency may cause neonatal jaundice, acute hemolysis, or severe chronic non-spherocytic hemolytic anemia. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
IKBKG (HGNC:5961): (inhibitor of nuclear factor kappa B kinase regulatory subunit gamma) This gene encodes the regulatory subunit of the inhibitor of kappaB kinase (IKK) complex, which activates NF-kappaB resulting in activation of genes involved in inflammation, immunity, cell survival, and other pathways. Mutations in this gene result in incontinentia pigmenti, hypohidrotic ectodermal dysplasia, and several other types of immunodeficiencies. A pseudogene highly similar to this locus is located in an adjacent region of the X chromosome. [provided by RefSeq, Mar 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
PP5
Variant X-154546061-T-C is Pathogenic according to our data. Variant chrX-154546061-T-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 10403.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chrX-154546061-T-C is described in Lovd as [Pathogenic]. Variant chrX-154546061-T-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
G6PD | NM_001360016.2 | c.95A>G | p.His32Arg | missense_variant | 2/13 | ENST00000393562.10 | NP_001346945.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
G6PD | ENST00000393562.10 | c.95A>G | p.His32Arg | missense_variant | 2/13 | 1 | NM_001360016.2 | ENSP00000377192 | P4 |
Frequencies
GnomAD3 genomes AF: 0.0000718 AC: 8AN: 111476Hom.: 0 Cov.: 23 AF XY: 0.000149 AC XY: 5AN XY: 33668
GnomAD3 genomes
AF:
AC:
8
AN:
111476
Hom.:
Cov.:
23
AF XY:
AC XY:
5
AN XY:
33668
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000148 AC: 27AN: 182995Hom.: 0 AF XY: 0.0000889 AC XY: 6AN XY: 67465
GnomAD3 exomes
AF:
AC:
27
AN:
182995
Hom.:
AF XY:
AC XY:
6
AN XY:
67465
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000264 AC: 29AN: 1097670Hom.: 0 Cov.: 30 AF XY: 0.0000138 AC XY: 5AN XY: 363060
GnomAD4 exome
AF:
AC:
29
AN:
1097670
Hom.:
Cov.:
30
AF XY:
AC XY:
5
AN XY:
363060
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000718 AC: 8AN: 111476Hom.: 0 Cov.: 23 AF XY: 0.000149 AC XY: 5AN XY: 33668
GnomAD4 genome
AF:
AC:
8
AN:
111476
Hom.:
Cov.:
23
AF XY:
AC XY:
5
AN XY:
33668
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
16
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:10Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Anemia, nonspherocytic hemolytic, due to G6PD deficiency Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 21, 2024 | This sequence change replaces histidine, which is basic and polar, with arginine, which is basic and polar, at codon 32 of the G6PD protein (p.His32Arg). This variant is present in population databases (rs137852340, gnomAD 0.2%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with G6PD deficiency (PMID: 10502785, 11601226, 16329560, 29339739, 30315739). It is commonly reported in individuals of Asian ancestry (PMID: 29339739). This variant is also known as G6PD Gaohe. ClinVar contains an entry for this variant (Variation ID: 10403). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt G6PD protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Aug 09, 2023 | - - |
Pathogenic, criteria provided, single submitter | curation | Dunham Lab, University of Washington | Aug 12, 2022 | Variant found in hemizygtes with G6PD deficiency, some with anemia and jaundice (PP4). Decreased activity in red blood cells of hemizygotes (0-38%) (PS3). Identified in unrelated individuals with G6PD deficiency (PS4_M). Modeling predicts disruption of function (PP3). Below expected carrier frequency in gnomAD (PM2). Post_P 0.994 (odds of pathogenicity 1517, Prior_P 0.1). - |
Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | May 27, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Feb 02, 2022 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with G6PD deficient haemolytic anaemia (favism). (I) 0109 - This gene is associated with X-linked recessive disease. Hemizygous males and homozygous females are commonly affected, however some heterozygous female carriers can also be affected depending on X inactivation. (I) 0200 - Variant is predicted to result in a missense amino acid change from histidine to arginine. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (22 heterozygotes, 0 homozygotes, 7 hemizygotes). (SP) 0502 - Missense variant with conflicting in silico predictions and uninformative conservation. (I) 0604 - Variant is not located in an established domain, motif, hotspot or informative constraint region. (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This founder mutation in Asian population that is also known as G6PD Gaohe have been reported in multiple individuals with G6PD deficiency (ClinVar, PMID: 29339739, 33051526). (SP) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Early-onset coronary artery disease Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 08, 2024 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 12, 2022 | The c.95A>G (p.H32R) alteration is located in exon 2 (coding exon 1) of the G6PD gene. This alteration results from an A to G substitution at nucleotide position 95, causing the histidine (H) at amino acid position 32 to be replaced by an arginine (R). Based on data from gnomAD, the G allele has an overall frequency of 0.014% (29/204635) total alleles studied. The highest observed frequency was 0.196% (29/14827) of East Asian alleles. This variant accounts for more than 20% of pathogenic alleles in the Chinese population and has been detected alone or in conjunction with another G6PD variant in individuals with G6PD deficiency (Chiu, 1993; Zhong, 2018; Chen, 2018; Fu, 2018; Ohlsson, 2019; He, 2020; Wang, 2021; Xu, 2021; Pan, 2021; Xu, 2022). This amino acid position is highly conserved in available vertebrate species. This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. - |
Malaria, susceptibility to;C2720289:Anemia, nonspherocytic hemolytic, due to G6PD deficiency Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 27, 2022 | - - |
Malaria, susceptibility to Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 24, 2024 | - - |
G6PD deficiency Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 08, 2024 | Variant summary: G6PD c.185A>G (p.His62Arg) [NM_001035810.1:c.95A>G (p.His32Arg)], also referred to as G6PD Gaohe/Gaozhou/Sapporo-like/Ube/Bodia-like, results in a non-conservative amino acid change located in the Glucose-6-phosphate dehydrogenase, NAD-binding domain (IPR022674) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00015 in 182995 control chromosomes predominantly in the East Asian population. This frequency is not significantly higher than estimated for a pathogenic variant in G6PD causing Glucose 6 Phosphate Dehydrogenase Deficiency (0.00015 vs 0.29), allowing no conclusion about variant significance. c.185A>G has been reported in the literature in multiple individuals affected with Glucose 6 Phosphate Dehydrogenase Deficiency and as a G6PD hotspot mutation in the Chinese population (example, Ainoon_1999, Fu_2018, Sun_2022). At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal G6PD enzyme activity (Ainoon_1999). The following publications have been ascertained in the context of this evaluation (PMID: 10502785, 29339739, 16607506, 36353116). ClinVar contains an entry for this variant (Variation ID: 10403). Based on the evidence outlined above, the variant was classified as pathogenic. - |
G6PD GAOHE Other:1
other, no assertion criteria provided | literature only | OMIM | Sep 05, 2023 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Pathogenic
D;D;D;.;T;.;T
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
.;.;D;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Uncertain
D;D;D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Uncertain
M;M;M;M;.;.;.
MutationTaster
Benign
D;D;D;D;D;D
PrimateAI
Uncertain
T
PROVEAN
Uncertain
.;.;D;D;D;D;D
REVEL
Pathogenic
Sift
Benign
.;.;T;T;T;T;D
Sift4G
Benign
T;.;T;T;.;.;.
Polyphen
D;D;D;.;.;.;.
Vest4
MutPred
Loss of disorder (P = 0.1672);Loss of disorder (P = 0.1672);Loss of disorder (P = 0.1672);Loss of disorder (P = 0.1672);Loss of disorder (P = 0.1672);Loss of disorder (P = 0.1672);Loss of disorder (P = 0.1672);
MVP
MPC
2.6
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at